Clinical Trial Update: Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dose-augmented rituximab with ICE chemotherapy in patients with primary refractory or poor-risk relapsed aggressive B-cell non-Hodgkin …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• IFOSFAMIDE (IFOSFAMIDE)
• Rituximab (rituximab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lymphoma, B-cell Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2015-12-04